Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting human EGFR 2 (HER2) in salivary gland carcinoma

28 Apr 2023

Abstract excerpt

INTRODUCTION: Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification, and activating mutations have been identified in a subset of salivary gland carcinoma (SGC) histologies (HER2-positive), especially in salivary duct carcinoma, and represent an important therapeutic target. AREAS COVERED: The evidence for targeting HER2 in the adjuvant setting is limited to small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Salivary Gland Disorders and Functions
Share to Salivary Gland Tumors Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37114470
DOI: 10.1080/14737140.2023.2208350

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting human EGFR 2 (HER2) in salivary gland carcinomaPMID 37114470Read ↗

[Salivary gland cancer: new therapeutic approaches].Semantic proximity Read ↗

Salivary gland carcinoma: Towards a more personalised approach.Semantic proximity Read ↗

Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers.Semantic proximity Read ↗

Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Semantic proximity Read ↗

Salivary Gland Cancers: Biology and Molecular Targets for TherapySemantic proximity Read ↗

Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.Semantic proximity Read ↗

Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Semantic proximity Read ↗

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profilingSemantic proximity Read ↗

Salivary gland cancers: current treatments, molecular characteristics and new therapies.Semantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

Salivary gland cancer: an update on present and emerging therapies.Semantic proximity Read ↗

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.